Notice for the Annual General Meeting of Novo Nordisk A/S
21 Februar 2024 - 3:03PM
Notice for the Annual General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 21 February 2024 – The
Annual General Meeting of Novo Nordisk A/S will be held on:
Thursday 21 March 2024 at 14.00
(CET)
The Annual General Meeting is held as a partially electronic
general meeting. Accordingly, shareholders can choose between
participating in person at Bella Center, Center Boulevard 5,
DK-2300 Copenhagen S, Denmark or participating virtually via an IT
application. We encourage shareholders to exercise their rights by
submitting proxies or votes by correspondence in advance of the
Annual General Meeting.
Also, Novo Nordisk offers the possibility of viewing the Annual
General Meeting via live webcast on Novo Nordisk’s website.
Please refer to the notice for further information. The notice
for the Annual General Meeting, including Appendix: Candidates for
the Board of Directors, is enclosed.
BOARD OF DIRECTORS All Board members elected by
the Annual General Meeting are up for election.
The Board of Directors proposes re-election of Helge Lund as
chair of the Board and re-election of Henrik Poulsen as vice chair.
Moreover, the Board proposes re-election of the following Board
members: Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Kasim
Kutay, Christina Law and Martin Mackay as members of the Board.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in
diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 63,400 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X,
LinkedIn and YouTube.
Contacts for further information
|
Media: |
|
| Ambre
James-Brown +45 3079 9289abmo@novonordisk.com |
Liz
Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com |
|
Investors: |
|
| Daniel
Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com |
Jacob
Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com |
| David
Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
Mark
Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com |
| Sina
Meyer +45 3079 6656azey@novonordisk.com |
Frederik
Taylor Pitter +45 3075 8259fptr@novonordisk.com |
Company announcement No 17 / 2024
- PR240221-AGM_notice-combined
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024
